Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Mar;13(1):75-9.
doi: 10.1007/BF02229869.

A clinical and biochemical assessment of methotrexate in rheumatoid arthritis

T J Tait  1 , P Le Gallez, C Astbury, H A Bird
Affiliations
Clinical Trial

A clinical and biochemical assessment of methotrexate in rheumatoid arthritis

T J Tait et al. Clin Rheumatol. 1994 Mar.

Abstract

Low-dose methotrexate has gained widespread acceptance as a second-line agent in rheumatoid arthritis (RA). The Leeds Human Model Screening System (LHMSS) is a validated screening mechanism allowing the rapid evaluation of compounds for their potential as anti-rheumatic agents, the results of which have been confirmed in longer term studies. We have evaluated methotrexate in patients with RA using the LHMSS at a maintenance dose of 10mg/week. Significant change occurred in four out of eleven variables over a 24-week period (p < 0.01). This degree of change is greater than that seen with nonsteroidal anti-inflammatory agents but less than with other recognised second-line agents such as D-penicillamine, suggesting that methotrexate may have less potential as a second-line agent than D-penicillamine.

PubMed Disclaimer

References

    1. Bull Rheum Dis. 1958 Dec;9(4):175-6 - PubMed
    1. J Rheumatol. 1984 Dec;11(6):760-3 - PubMed
    1. Am J Med Sci. 1951 Feb;221(2):176-82 - PubMed
    1. Ann Rheum Dis. 1992 Aug;51(8):1019-20 - PubMed
    1. Semin Arthritis Rheum. 1982 Nov;12(2):185-90 - PubMed

Publication types

MeSH terms